Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-25
2011-01-25
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S113000
Reexamination Certificate
active
07875626
ABSTRACT:
The present invention relates to 4,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one and 4,5-dihydropyrrolo[3,2-c]pyridin-4-one compounds of formula (I) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.
REFERENCES:
patent: 5462960 (1995-10-01), Barth et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 6344474 (2002-02-01), Maruani et al.
patent: 7576095 (2009-08-01), Cheng
patent: 2004/0038980 (2004-02-01), Lam et al.
patent: WO 01/70700 (2001-09-01), None
patent: WO 03/027114 (2003-04-01), None
patent: WO 2005/080328 (2005-09-01), None
patent: WO 2005/080343 (2005-09-01), None
patent: WO 2005/095354 (2005-10-01), None
Lim Shiang et al., Basic research in cardiology, (Nov. 2009) vol. 104, No. 6, pp. 781-792.
Donald L Hertzog “Recent advances in the cannabinoids” Expert Opinion on Therapeutic Patents 14(10):1435-1452 (2004).
Katoch-Rouse et al. “Synthesis, structure-activity relationship, and evaluation of. SR141716 analogues: Development of central cannabinoid receptor ligands with lower lipophilicity” Journal of Medicinal Chemistry 46(4):642-645 (2003).
Lange et al. “Bioisosteric Replacements of the Pyrazole Moiety of Rimonabant: Synthesis, Biological Properties, and Molecular Modeling Investigations of Thiazoles, Triazoles, and Imidazoles as Potent and Selective CB1 Cannabinoid Receptor Antagonists” Journal of Medicinal Chemistry 48:1823-1838 (2005).
Palmer et al. “Cannabinergic ligands” Chemistry and Physics of Lipids 121:3-19 (2002).
Smith et al. “Constrained analogs of CB-1 antagonists: 1,5,6,7-Tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one derivatives” Bioorganic & Medicinal Chemistry Letters 17(3): 673-678 (2007).
Smith et al. “Constrained analogs of CB-1 antagonists for the treatment of obesity: Design, synthesis, and pharmacology of 1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one derivatives” Advance Notice of Presentation by R.A. Smith at 230th ACS National Meeting, in Washington DC, Aug. 28-Sep. 1, 2005.
Notes taken by AstraZeneca employee Lanna Li at presentation by R.A. Smith at 230th ACS National Meeting, in Washington DC, Aug. 28-Sep. 1, 2005.
Mackie “Cannabinoid receptors as therapeutic targets” Annu. Rev. Pharmacol. Toxicol. 46:101-122 (2006).
Marzo “CB1 receptor antagonism: Biological basis for metabolic effects” Drug Discovery Today, 13:1026-1041 (2008).
Wermuth “Molecular variations based on isotonic replacements” The Practice of Medicinal Chemistry, Academic Press Limited, 204-228 (1996).
Xie et al. “The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism—or inverse agonism—as potential obesity treatment and other therapeutic use” Journal of Clinical Pharmacy and Therapeutics 32(3): 209-231 (2007).
Astrazeneca AB
Morgan & Lewis & Bockius, LLP
Rahmani Niloofar
Seaman D. Margaret
LandOfFree
Therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2654123